LENZ Therapeutics reports Q4 2025 net product revenue $1.6M from VIZZ launch; net loss $35.9M

LENZ Therapeutics, Inc.

Q4 net product revenue $1.6M from VIZZ aceclidine eye drop for presbyopia; over 20,000 filled prescriptions.
Net loss $35.9M ($1.16 per share) for Q4 2025 vs $12.7M in Q4 2024; cash $292.3M at year-end.
Over 6,500 unique prescribers in Q4, on pace for 10,000+ through Q1 2026; >55% wrote multiple times.
Sales force expanding from 88 to 117 territories in Q2 2026; MAA submitted to EMA in March 2026.
Launched 'Make it VIZZable' DTC campaign with Sarah Jessica Parker; website traffic up 10x.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LENZ Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $1.6 million.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $1.6 million
Result: reported results

Exact text from the filing

and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001815776-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.